Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

XX1XX Oct. 27 at 3:59 PM

$AUTL the BlueBird hangover is real. Scam St is saying having a cure is not enough in this space due to the complexity of the procedure and terrible COGS numbers. Once again we are back to show me the money as not even a legit cure for Lupus is moving the stock.

1 · Reply

Michael_garic Oct. 27 at 3:39 PM

$AUTL a lot of chunk buying on the exchange today and not much selling... mainly shorts selling in small bits trying their best to kill the rally

0 · Reply

wussel Oct. 27 at 3:34 PM

$AUTL What's up? Did investors finally wake up?

0 · Reply

keypatience Oct. 27 at 3:33 PM

$AUTL

0 · Reply

MedHS55 Oct. 27 at 3:29 PM

$AUTL I guess somebody woke up and realizes this was good news..

1 · Reply

GeniusLoci Oct. 27 at 2:57 PM

$AUTL Remarkable safety and efficacy lupus data. A BP head-turner

0 · Reply

wussel Oct. 27 at 2:51 PM

$AUTL I think the next step to watch is how fast they can recruit patients for phase 2. One would think that if the results of phase 1 spread among affected patients, the recruiting should be finished quite fast.

0 · Reply

alexpitti Oct. 27 at 2:35 PM

I guess I was right. Friday was the last day to buy Autolus before the data. However, investors don't care about the great data like many predicted. $AUTL

0 · Reply

keypatience Oct. 27 at 2:34 PM

$AUTL Yes but very small sample size: n=6 limits generalizability and Median follow-up 8.9 months limits long-term durability evidence

1 · Reply

QHD Oct. 27 at 2:28 PM

$AUTL This is incredible news! 83% remission in Lupus!!! 50% had Kidney Restoration! Obe-cel is showing to be a wonder-drug!

0 · Reply

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Oct 20, 2025, 7:00 AM EDT - 7 days ago

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Oct 15, 2025, 4:05 PM EDT - 11 days ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 16, 2025, 8:05 AM EDT - 5 weeks ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Aug 12, 2025, 5:26 PM EDT - 2 months ago

Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable

Aug 12, 2025, 4:37 PM EDT - 2 months ago

Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:00 AM EDT - 2 months ago

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jul 24, 2025, 7:30 AM EDT - 3 months ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

$Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

Jul 21, 2025, 7:00 AM EDT - 3 months ago

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Jun 12, 2025, 2:00 AM EDT - 4 months ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 6, 2025, 11:09 AM EDT - 5 months ago

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market

May 29, 2025, 4:05 PM EDT - 5 months ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025, 8:30 AM EDT - 5 months ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 20, 2025, 5:47 AM EDT - 5 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC CAPR CLPT EDIT NTLA VANI VERV

May 14, 2025, 9:30 AM EDT - 5 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 11, 2025, 4:22 AM EDT - 6 months ago

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 6 months ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 6 months ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 22, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 2, 2025, 7:00 AM EDT - 7 months ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 7 months ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 11:55 AM EDT - 7 months ago

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 6, 2025, 7:00 AM EST - 8 months ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Mar 4, 2025, 10:21 AM EST - 8 months ago

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Jan 17, 2025, 7:00 AM EST - 10 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 11 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Nov 21, 2024, 12:16 AM EST - 1 year ago

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 12, 2024, 2:57 PM EST - 1 year ago

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 1 year ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 1 year ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Sep 6, 2024, 2:12 PM EDT - 1 year ago

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Aug 10, 2024, 12:05 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

May 31, 2024, 8:00 AM EDT - 1 year ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 17, 2024, 12:55 PM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript

May 17, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 1:02 PM EDT - 1 year ago

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

Apr 24, 2024, 10:00 AM EDT - 1 year ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Announces Changes to its Board of Directors

Mar 15, 2024, 5:23 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Feb 29, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Feb 8, 2024, 7:00 AM EST - 1 year ago

Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 5:45 AM EST - 1 year ago

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Feb 6, 2024, 9:52 AM EST - 1 year ago

Autolus Upgrades Leadership And Faces CAR-T Approval

XX1XX Oct. 27 at 3:59 PM

1 · Reply

Michael_garic Oct. 27 at 3:39 PM

$AUTL a lot of chunk buying on the exchange today and not much selling... mainly shorts selling in small bits trying their best to kill the rally

0 · Reply

wussel Oct. 27 at 3:34 PM

$AUTL What's up? Did investors finally wake up?

0 · Reply

keypatience Oct. 27 at 3:33 PM

$AUTL

0 · Reply

MedHS55 Oct. 27 at 3:29 PM

$AUTL I guess somebody woke up and realizes this was good news..

1 · Reply

GeniusLoci Oct. 27 at 2:57 PM

$AUTL Remarkable safety and efficacy lupus data. A BP head-turner

0 · Reply

wussel Oct. 27 at 2:51 PM

0 · Reply

alexpitti Oct. 27 at 2:35 PM

I guess I was right. Friday was the last day to buy Autolus before the data. However, investors don't care about the great data like many predicted. $AUTL

0 · Reply

keypatience Oct. 27 at 2:34 PM

$AUTL Yes but very small sample size: n=6 limits generalizability and Median follow-up 8.9 months limits long-term durability evidence

1 · Reply

QHD Oct. 27 at 2:28 PM

$AUTL This is incredible news! 83% remission in Lupus!!! 50% had Kidney Restoration! Obe-cel is showing to be a wonder-drug!

0 · Reply

TricksterT Oct. 27 at 1:59 PM

$AUTL

0 · Reply

wussel Oct. 27 at 1:58 PM

$AUTL The presentation tomorrow is supposed to last two hours, so jut reading the information from today's PR will not be enough to fill these two hours. I am looking forward to the actual presentaion material which will hopefully be availble online

1 · Reply

XX1XX Oct. 27 at 1:55 PM

$SNDX learn from $AUTL - now that you have FDA approval expect a new 52week low. This is the new Scam St. playbook. COGS and Revenue will be the only thing that matters.

1 · Reply

XX1XX Oct. 27 at 1:15 PM

$AUTL what chatgpt thinks about the news: Rating: 9/10 The release is highly positive and data-rich, clearly demonstrating both safety and efficacy in a small but meaningful cohort. It effectively positions obe-cel as a breakthrough candidate in lupus treatment.

0 · Reply

XX1XX Oct. 27 at 1:14 PM

$AUTL wow. another great news release and nobody cares. wtf is up with this stock.

1 · Reply

Michael_garic Oct. 27 at 11:52 AM

$AUTL increased short interest makes no sense???

2 · Reply

JcoalX Oct. 27 at 11:42 AM

$AUTL premarket pump, followed by some dude that dumps his shares…… let’s break this cycle!

1 · Reply

wussel Oct. 27 at 11:09 AM

$AUTL Short interest increased by appr. 400,000 to 11,8 million shares, hopefully this time short sellers can not cover cheaply like they did last time thanks to brainless Wellington selling https://www.nasdaq.com/market-activity/stocks/autl/short-interest

1 · Reply

RonIsWrong Oct. 27 at 11:06 AM

$AUTL Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025 Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal study Preliminary efficacy data demonstrate achievement of definition of remission in SLE (DORIS) in 83% of patients and complete renal response (CRR) in 50% of patients; all responses and remissions are ongoing with no evidence of disease activity at a median follow-up of 8.9 months All patients had refractory lupus nephritis; 4/6 patients had significantly impaired kidney function Patients received no other lupus directed therapy; steroids were tapered in all patients to 5mg by month six Company remains on track to dose first patient in Phase 2 trial in lupus nephritis (LN) by year-end 2025

0 · Reply

keypatience Oct. 27 at 9:11 AM

$AUTL Autolus Therapeutics will present updated clinical data from its Phase I CARLYSLE study (obecabtagene autoleucel, or obe-cel) for severe refractory systemic lupus erythematosus on Tuesday, October 28, 2025.

0 · Reply

MobyDick2324 Oct. 27 at 4:42 AM

$AUTL big week guys…

1 · Reply

Flying_Trader2 Oct. 27 at 3:31 AM

$AUTL I wonder if the RNA Novartis deal will have any affect on AUTL, scientifically they are in the same neck of the woods, no?

1 · Reply

Market Cap	407.20M
Revenue (ttm)	10.12M
Net Income (ttm)	-220.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,180.43%
Debt to Equity Ratio	0.00

Volume	4,110,083
Avg Vol	4,059,766
Day's Range	N/A - N/A
Shares Out	266.14M
Stochastic %K	10%
Beta	1.84
Analysts	Strong Sell
Price Target	$9.59